Elsevier

The Lancet

Volume 379, Issue 9819, 10–16 March 2012, Pages 870-871
The Lancet

Comment
Cardiac regeneration: messages from CADUCEUS

https://doi.org/10.1016/S0140-6736(12)60236-0Get rights and content

References (11)

There are more references available in the full text version of this article.

Cited by (26)

  • Cardiac cell therapy: Current status and future trends

    2014, Cardiac Regeneration and Repair
  • Importance of insulin resistance to vascular repair and regeneration

    2013, Free Radical Biology and Medicine
    Citation Excerpt :

    Although not yet studied, vector targeting of signaling molecules downstream of multiple growth factors may also prove effective in bypassing growth factor resistance and so augmenting vascular renewal; however, more significant side effects might also be anticipated. Clinical trials of diverse autologous and allogeneic cell lines in the context of ischemic heart disease are currently ongoing, with mixed success in terms of surrogate outcomes; adequately powered studies of hard clinical outcomes are awaited [271–273]. These studies have not specifically recruited patients with insulin resistance or diabetes, yet such patients are likely to represent a majority in any cohort with established ischemic heart disease [9].

  • Towards regenerative therapy for cardiac disease

    2012, The Lancet
    Citation Excerpt :

    These results led to the initiation of several phase 1 clinical trials involving heart-derived cells: ALCADIA (NCT00981006), SCIPIO (NCT00474461), and CADUCEUS (NCT00893360). Preliminary results from the SCIPIO and CADUCEUS trials were recently published.38–40 Both studies were designed to assess the feasibility and safety of intracoronary injection of autologous heart-derived cells after recent infarction.

View all citing articles on Scopus
View full text